Efficacy of etanercept in the tumor necrosis factor receptor-associated periodic syndrome: a prospective, open-label, dose-escalation study.

ABSTRACT:

Objective

To investigate the efficacy of etanercept in improving the symptoms and underlying inflammation in patients with tumor necrosis factor receptor-associated periodic syndrome (TRAPS).

Methods

Fifteen patients with TRAPS were enrolled in a prospective, open-label, dose-escalation study. Patients recorded attacks, symptom severity, and use of ancillary medications in a daily diary. Blood samples were collected during each period and measured for levels of acute-phase reactants. Between 7 years and 9 years after the conclusion of the initial study, patients completed a followup survey and were evaluated to determine the long-term outcome of etanercept treatment.

Results

Etanercept treatment significantly attenuated the total symptom score and reduced the frequenc

SUBMITTER: Bulua AC 

PROVIDER: S-EPMC3882089 | biostudies-literature | 2012 Mar

REPOSITORIES: biostudies-literature